PMID- 27069548
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160412
LR  - 20220317
IS  - 1943-8141 (Print)
IS  - 1943-8141 (Electronic)
IS  - 1943-8141 (Linking)
VI  - 8
IP  - 1
DP  - 2016
TI  - Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong 
      staining of CyclinD1 could have same predictive roles as CCND1 amplification in 
      ER positive breast cancers.
PG  - 142-53
AB  - CCND1 is amplified in around 10-20% of primary breast cancers and preferentially 
      occurs in ER positive tumors. Though CCND1 amplification was reported predicting 
      poor response of adjuvant tamoxifen treatment and poor prognosis in ER positive 
      breast cancers, there were controversial data regarding the predicting value of 
      CyclinD1 protein overexpression. In this study, we detected CyclinD1 expression 
      using immunohistochemistry and CCND1 gene copy number using fluorescence in situ 
      hybridization (FISH) in 355 invasive breast cancers with foci ductal carcinoma in 
      situ (DCIS). CCND1 amplification was founded in 52 (14.6%) cases all of which 
      showed moderate to strong CyclinD1 expression. However, majority of CCND1- tumors 
      exhibited mild to moderate CyclinD1 staining. There were identical alterations in 
      DCIS and the invasive lesions within the same tumor. CCND1 amplification was 
      positively correlated with ER, PR and lymph node status (P<0.001) while 
      negatively correlated with HER-2 amplification and p53 status (P<0.05). The 
      majority of the CCND1 amplification/high CyclinD1 breast cancers were luminal B 
      type while basal-like type often lost the expression of this protein. The ROC 
      curve analysis showed that a cut-off point at which the immunostaining score of 
      CyclinD1 is 6.5 could predict CCND1 gene amplification in breast cancer. This 
      study indicated loss expression of CyclinD1 might be an important event in the 
      tumorigenesis in basal-like breast cancers. Further, we confirmed an optimal 
      cut-off point of immunostaining scores of CyclinD1 protein which could be used to 
      predict the status of CCND1 gene and identify a subgroup of ER positive breast 
      cancers with poor response to endocrine agents.
FAU - Li, Zhishuang
AU  - Li Z
AD  - Department of Pathology, Shandong University, School of Medicine 44 Wenhua Xi 
      Road, Jinan, Shandong, 250012, P.R. China.
FAU - Cui, Jingjing
AU  - Cui J
AD  - Shandong University, School of Medicine 44 Wenhua Xi Road, Jinan, Shandong 
      Province, 250012, P.R. China.
FAU - Yu, Qiong
AU  - Yu Q
AD  - The Central Hospital of Zaozhuang Mining Group P.R. China.
FAU - Wu, Xiaojuan
AU  - Wu X
AD  - Department of Pathology, Shandong University, School of Medicine 44 Wenhua Xi 
      Road, Jinan, Shandong, 250012, P.R. China.
FAU - Pan, Aifeng
AU  - Pan A
AD  - Department of Pathology, Shandong University, School of Medicine 44 Wenhua Xi 
      Road, Jinan, Shandong, 250012, P.R. China.
FAU - Li, Li
AU  - Li L
AD  - Department of Pathology, Shandong University, School of Medicine 44 Wenhua Xi 
      Road, Jinan, Shandong, 250012, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20160115
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC4759424
OTO - NOTNLM
OT  - CCND1
OT  - Cyclin D1
OT  - breast cancer
OT  - predictive markers
OT  - target therapy
EDAT- 2016/04/14 06:00
MHDA- 2016/04/14 06:01
PMCR- 2016/01/15
CRDT- 2016/04/13 06:00
PHST- 2015/10/12 00:00 [received]
PHST- 2015/11/21 00:00 [accepted]
PHST- 2016/04/13 06:00 [entrez]
PHST- 2016/04/14 06:00 [pubmed]
PHST- 2016/04/14 06:01 [medline]
PHST- 2016/01/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Transl Res. 2016 Jan 15;8(1):142-53. eCollection 2016.